Roivant Telavant Acquisition by Roche 2023

Roivant announced the sale of its Telavant subsidiary to Roche for $7.1 billion upfront plus $150 million in milestone payments. The transaction includes development and commercial rights to RVT-3101 in the US and Japan, with Pfizer retaining rights outside these regions. Expected to close in Q4 2023 or Q1 2024.